Lipella Pharmaceuticals
LIPO
LIPO was delisted on the 18th of June, 2025.
5 hedge funds and large institutions have $39.7K invested in Lipella Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 3 closing their positions.
0.9% less ownership
Funds ownership: 1.04% → 0.13% (-0.9%)
29% less funds holding
Funds holding: 7 → 5 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
86% less capital invested
Capital invested by funds: $284K → $39.7K (-$244K)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$8.46K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$243K |
| 2 |
Two Sigma Investments
New York
|
-$5.84K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$3.95K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$523 |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$12 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Vanguard Group
Malvern,
Pennsylvania
| $16.3K | – | – | – |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $11.8K | -$523 | -136 | -4% |
|
|
HF
3
HRT Financial
New York
| $8K | +$8.46K | +2,202 | New |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $3.63K | -$12 | -3 | -0.3% |
|
5
Bank of America
Charlotte,
North Carolina
| $22 | – | – | – |
|
|
SM
6
Sabby Management
Miami Beach,
Florida
| – | -$243K | -67,531 | Closed |
|
|
7
Two Sigma Investments
New York
| – | -$5.84K | -1,623 | Closed |
|
|
8
UBS Group
Zurich,
Switzerland
| – | -$3.95K | -1,097 | Closed |
|
LIPO Hedge Fund Activity: Q3 2024 in Review
5 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Lipella Pharmaceuticals (LIPO) for Q3 2024, worth a combined $39.7K — down 86% from $284K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of LIPO and 1 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 0 added.
The largest buyer was HRT Financial, opening a new position worth an estimated $8.46K. The largest seller was Sabby Management, exiting entirely with an estimated $243K sold.
- 5 institutional investors held Lipella Pharmaceuticals (LIPO) as of Q3 2024, down from 7 in Q2 2024.
- Funds reported $39.7K of Lipella Pharmaceuticals stock for Q3 2024, down 86% quarter-over-quarter.
- 1 fund opened new Lipella Pharmaceuticals positions in Q3 2024 and 3 closed out, a net change of -2 holders.
- The largest Lipella Pharmaceuticals buyer in Q3 2024 was HRT Financial, an estimated $8.46K added.
- The largest Lipella Pharmaceuticals seller in Q3 2024 was Sabby Management, an estimated $243K sold.
Based on aggregated 13F filings for Q3 2024.